We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » VALIDATION OF STABILITY STUDIES MUST BE EXPLICIT, NEW GUIDANCE STATES
VALIDATION OF STABILITY STUDIES MUST BE EXPLICIT, NEW GUIDANCE STATES
January 6, 2004
Manufacturers submitting stability data in support of new drug applications (NDAs) and abbreviated new drug applications (ANDAs) need to identify the analytical procedures used to generate the data, according to a draft guidance released by the FDA yesterday.